摘要西妥昔单抗(cetuximab)治疗胃癌和食管癌的研究尚处于初期.含西妥昔单抗一线方案的疾病控制率为72.7%～92%,中位总生存为9.5～16.6个月,无进展生存期或肿瘤进展时间为6.2～11个月.含西妥昔单抗二线方案具有可以克服伊立替康和多西紫杉醇耐药性的特点,其与同步放化疗联合行术前诱导治疗,病理完全缓解率为13%～65%.在预测疗效方面18F标记的脱氧葡萄糖-正电子断层发射显像术(18F-FDG-PET)显示了一定的作用,而K-ras基因突变则无价值.

abstractsFew studies of cetuximab on patients with gastric and esophageal cancer were available now.The disease control rate was 72.7%～92%,OS was 9.5～16.6months,PFS/was 6.2～11 months among first-line setting with cetuximab-contained regimens.And cetuximab shown in second-line regimen setting overcome the resistance of irinotecan and docetaxel.The pCR was 13%～65% when cetuximab was used as induction treatment combined with concurrent chemoradiation.18F-FDG-PET was a potential method to predictthe efficacy of cetuximab-contained regimens,however,status of Kras gene had no predictive value.